EPIDEMIOLOGY OF MALIGNANT TUMORS OF LARGE SALIVARY GLANDS (POPULATION-BASED STUDY)

Abstract

Introduction. Malignant tumors of large salivary glands are a relatively rare malignancy. In 2014 as a whole in Russia 1236 cases of these diseases were registered. According to the latest data of the Interna- tional Agency for Research on Cancer (Volume X) the most common standardized incidence rate in various countries ranges from 0.6-0.9 per 100,000 men and 0.4-0.6 per 100,000 women. aim of study. The aim of this study is to carry out for the first time in Russia an estimation of a complex of analytical rates including an evaluation of observed and relative survival rates to assess the effectiveness of cancer control related to patients with a diagnosis of malignant tumors of large salivary glands. material and methods. An estimation of a complex of analytical rates was conducted in accordance with database of the Population-based Cancer Registry of St. Petersburg. There were selected 896 patients with a diagnosis of malignant tumors of large salivary glands from 1994 to 2013. Results. It was found that the most frequent value of the standardized incidence rates of malignant tumors of large salivary glands in different countries of the world community for the male population was 0.6-0.9 per 100,000 population and 0.4-0.6 for the female. These values were 0000 equal to 0.7 and 0.4 0/ in Russia (2014), and 0.6 and 0.5 0/ in St. Petersburg (2014). The vast majority 0000 of recorded cases of malignant tumors of large salivary glands were for S07.9 - of malignant tumors of large salivary glands undefined. 46.6 % of primary patients had early stages (I + II). A relative 5-year survival rate was 61.9 % for men and 69.9 % for women, which was slightly less than the European average (Eurocare). Conclusion. This study for the first time in Russia allowed estimating series of analytical rates character- izing the effectiveness of cancer control related to patients with malignant tumors of large salivary glands in St. Petersburg including estimations of a 5-year relative survival of patients.